Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-11T22:52:33.019Z Has data issue: false hasContentIssue false
  • English
  • Français

Recent Developments in Health Law

Published online by Cambridge University Press:  01 January 2021

Miranda Biven ,
A. Wade Noman ,
Brendan Murphy ,
Jamie Kohen ,
Alison E. Cantor ,
Jack P. Smith III  and
Laura Steiner
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Article
Information
Journal of Law, Medicine & Ethics , Volume 27 , Issue 1 , Spring 1999 , pp. 95 - 106
Copyright
Copyright © American Society of Law, Medicine and Ethics 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

See National Institutes of Health, Fact Sheet: Stem Cell Research (dated Jan. 19, 1999) (visited Feb. 23, 1999) <http://www.nih.gov/news/pr/jan99/od~19.htm> [hereinafter Fact Sheet: Stem Cell Research].+[hereinafter+Fact+Sheet:+Stem+Cell+Research].>Google Scholar
In normal conditions, stem cells have the potential to divide approximately fifty times, but scientists have developed techniques that increase that number to as many as 200 times. See Easterbrook, G., “Medical Evolution,” New Republic, Mar. 1, 1999, at 21.Google Scholar
See National Institute of Health, Pluripotent Stem Cells: A Primer (dated Jan. 28, 1999) (visited Feb. 23, 1999) <http://www.nih.gov/news/stemcell/primer.htm> [hereinafter Pluripotent Stem Cells].+[hereinafter+Pluripotent+Stem+Cells].>Google Scholar
The University of Wisconsin has a media kit on stem cell research and on James Thompson's work. See Stem Cell Press Kit (visited Mar. 16, 1999) <http://www.news.wisc.edu/emediakit>..' href=https://scholar.google.com/scholar?q=The+University+of+Wisconsin+has+a+media+kit+on+stem+cell+research+and+on+James+Thompson's+work.+See+Stem+Cell+Press+Kit+(visited+Mar.+16,+1999)+.>Google Scholar
See Hearing on Stem Cell Research Before the Subcomm. on Labor, Health and Human Service, and Education of the Senate Comm. on Appropriations (Dec. 2, 1998) (statement of Dr. Harold Varmus, Director, National Institutes of Health) (visited Feb. 23, 1999) <http://www.nih.gov/welcome/director/120298.htm>..>Google Scholar
See id. at 3; and Fact Sheet: Stem Cell Research, supra note 1. Geron Corporation owns the license to the stem cell discoveries made by Thomson and John Gearhart.Google Scholar
The announcement of this experiment prompted President Clinton to request, on November 14, 1998, that the National Bioethics Advisory Committee (NBAC) consider the ethical implications of such research. See letter from Bill Clinton, President, to Harold Shapiro, Chair, National Bioethics Advisory Commission (dated Nov. 14, 1998) (visited Feb. 27, 1999) <http://www.bioethics.gov/clinton_letter.html>. NBAC responded to the President's concerns on November 20, 1998, and indicated that the issues would also be addressed in NBAC's report on human stem cell research. See letter from Shapiro, Harold T., Chair, National Bioethics Advisory Commission, to Bill Clinton, President (dated Nov. 20, 1998) (visited Feb. 27, 1999) <http://www.bioethics.gov/shapiro_letter.html>..' href=https://scholar.google.com/scholar?q=The+announcement+of+this+experiment+prompted+President+Clinton+to+request,+on+November+14,+1998,+that+the+National+Bioethics+Advisory+Committee+(NBAC)+consider+the+ethical+implications+of+such+research.+See+letter+from+Bill+Clinton,+President,+to+Harold+Shapiro,+Chair,+National+Bioethics+Advisory+Commission+(dated+Nov.+14,+1998)+(visited+Feb.+27,+1999)+.+NBAC+responded+to+the+President's+concerns+on+November+20,+1998,+and+indicated+that+the+issues+would+also+be+addressed+in+NBAC's+report+on+human+stem+cell+research.+See+letter+from+Shapiro,+Harold+T.,+Chair,+National+Bioethics+Advisory+Commission,+to+Bill+Clinton,+President+(dated+Nov.+20,+1998)+(visited+Feb.+27,+1999)+.>Google Scholar
See Pluripotent Stem Cells, supra note 3.Google Scholar
See Omnibus Consolidated and Emergency Supplemental Appropriations Act, Fiscal Year 1999, Pub. L. No. 105-277, §§ 511-513 (1999).Google Scholar
Compare the Code of Federal Regulation, which defines “human subject” as “a living individual about whom an investigator (whether professional or student) conducting research obtains (1) data through intervention or interaction with the individual, or (2) identifiable private information.” 45 C.F.R. § 46.102 (1998).Google Scholar
As paraphrased by Harold Varmus. See Hearing on Stem Cell Research: HHS Legal Ruling Before the Subcomm. on Labor, Health and Human Service, and Education of the Senate Comm. on Appropriations (Jan. 26, 1999) (statement of Dr. Harold Varmus, Director, National Institutes of Health) (visited Feb. 23, 1999) <http://www.senate.gov/~appropriations.labor.varmus.htm>..>Google Scholar
“Human fetal tissue” is defined as “tissue or cells obtained from a dead human embryo or fetus after a spontaneous or induced abortion, or after a stillbirth.” Public Health Service Act, § 498A, 42 U.S.C. § 289g-1(g) (1994 & Supp. II 1996).Google Scholar
In addition to President Clinton's ban on federal funding of human cloning research, legislation has been proposed to prevent cloning of humans. In 1998, the Human Cloning Prohibition Act was proposed in Congress to prohibit cloning, but further action on the bill has been delayed. See S. 1601, 105th Cong. (1998). The Prohibition of Cloning of Human Beings Act, which limited the uses of somatic cell nuclear transfer, was also proposed. See S. 1611, 105th Cong. (1998).Google Scholar
See Pimley, D.W., “Research: NIH Says Federal Law No Bar to Financing Stem Cell Research; Senate Support Sought,” 8 Health Law Reporter (BNA), at 131 (1999).Google Scholar
See NIH Position on Human Pluripotent Stem Cell Research (visited Mar. 11, 1999) <http://www.nih.gov/grants/policy/stemcells.htm>..>Google Scholar
See supra note 7.Google Scholar
See 45 C.F.R. §§ 46.201–.211 (1998).Google Scholar
See Hearing on Stem Cell Research, supra note 11.Google Scholar
See Andrews, L., “Legal, Ethical and Social Concerns in the Debate over Stem Cells,” Chronicles of Higher Education, Jan. 29, 1999, at B4.Google Scholar
See Public Health Service Act, § 498A, 42 U.S.C. § 289(g)-289g-2 (1994 & Supp. II 1996). The National Organ Transplant Act prohibits interstate acquisition, receipt, or any other transfer of a “human organ for valuable consideration for use in human transplantation.” 42 U.S.C. § 274e (1994). The term “organ” also includes fetal tissue and organs. See 42 U.S.C. § 273a (1994). State legislation regulating fetal tissue research is applicable to both privately and publicly funded research. See Uniform Anatomical Gift Act, 8 U.L.A 29–61 (1987).Google Scholar
NIH's budget in fiscal year 1999 is $15.6 million (a 14.4 percent increase on its budget in 1998). NIH has been allocated $15.9 million for the fiscal year 2000. See National Institutes of Health, Press Briefing: FY 2000 President's Budget (visited Feb. 23, 1999) <http://www4.od.nih.gov/ofm/budget/pressbriefing.stm>..' href=https://scholar.google.com/scholar?q=NIH's+budget+in+fiscal+year+1999+is+$15.6+million+(a+14.4+percent+increase+on+its+budget+in+1998).+NIH+has+been+allocated+$15.9+million+for+the+fiscal+year+2000.+See+National+Institutes+of+Health,+Press+Briefing:+FY+2000+President's+Budget+(visited+Feb.+23,+1999)+.>Google Scholar
Legislation in many states currently bans embryo research, to varying degrees. See Fla. Stat. Ann. § 390.0111(5) (West Supp. 1998); La. Rev. Stat. Ann. § 9:122 (West 1991); Me. Rev. Stat. Ann. tit. 22, § 1593 (West 1992); Mass. Ann. Laws ch. 112, § 12J (Law. Co-op. 1991); Mich. Comp. Laws Ann. § 333.2685 (West 1992); Minn. Stat. Ann. § 145.422 (West 1989); N.H. Rev. Stat. Ann. § 168-B:15 (1994); N.D. Cent. Code § 14–02.2–01 (1991); 18 Pa. Cons. Stat. Ann. § 3216 (West Supp. 1997); and R.I. Gen. Laws § 11-54-1 (1994).Google Scholar
See Alpers, A. and Lo, B., “Commodification and Commercialization in Human Embryo Research,” Stanford Law Policy Review, 6 (1995): 39–46.Google Scholar
A group of Italian scientists have also announced that stem cells taken from the brains of adult transgenic mice have successfully been turned into blood cells. Further research is necessary to determine whether stem cells similarly obtained from the brains of adult humans can be turned into blood cells or any other type of cell. See Bovsun, M., “Italian Bio-chemists Turn Brain Stem Cells into Blood,” Biotechnology Newswatch, Feb. 1, 1999, at 1.Google Scholar
See Andrews, supra note 19.Google Scholar
Institutional avoidance of a policy position in relation to fetal or embryo rights, which may offend some portion of the population, is illustrated by the decision in Roe v. Wade. Justice Blackmun, delivering in the opinion of the Court, stated: “When those trained in the respective disciplines of medicine, philosophy, and theology are unable to arrive at any consensus, the judiciary, at this point in the development of man's knowledge, [is] not in a position to speculate as to the answer.” Roe v. Wade, 410 U.S. 113, 159 (1973).Google Scholar
Recer, P., “Working Using Fetal Cells Draws Fire,” Boston Globe, Feb. 18, 1999, at A10.Google Scholar
Recer, P., “Stem Cell Research to Proceed,” Wisconsin State Journal, Feb. 24, 1999, at 5A. A letter signed by seven senators sent to Secretary Donna Shalala voiced similar objections. See Recer, P., “Shalala Defends Stem Cell Use,” Boston Globe, Feb. 24, 1999, at A11.Google Scholar
Hearing on Stem Cell Research: HHS Legal Ruling Before the Subcomm. on Labor, Health and Human Service, and Education of the Senate Comm. on Appropriations (Jan. 26, 1999) (statement of Richard M. Doerflinger, Committee for Pro-life Activities, National Conference of Catholic Bishops) (visited Mar. 11, 1999) >http://www.senate.gov/~appropriations/abor/Doef1-26-99.htm>.http://www.senate.gov/~appropriations/abor/Doef1-26-99.htm>.>Google Scholar
See National Institutes of Health, Fact Sheet: Stem Cell Research (dated Jan. 28, 1999) (visited Feb. 23, 1999) <http://www.nih.gov/news/pr/jan99/od-28.htm>. Concerns about private control are not completely eliminated by federal funding of research projects. NIH exploits the commercial potential of genes discovered by federally funded scientists and also encourages researchers to enter into joint ventures with private companies. See Andrews, supra note 19..+Concerns+about+private+control+are+not+completely+eliminated+by+federal+funding+of+research+projects.+NIH+exploits+the+commercial+potential+of+genes+discovered+by+federally+funded+scientists+and+also+encourages+researchers+to+enter+into+joint+ventures+with+private+companies.+See+Andrews,+supra+note+19.>Google Scholar

References

Goodrich v. Aetna U.S. Healthcare, Inc., No. RCV020499 (Cal. App. Dep't Super. Ct. Jan. 20, 1999).Google Scholar
See Marquis, J., “Jury Returns Record Award Against HMO,” Los Angeles Times, Jan. 21, 1999, at Al.Google Scholar
See “Liability: California Jury Awards Record Damages Against Aetna for Treatment Decision,” Health Law Reporter (BNA), at 32 (Jan. 28, 1999) [hereinafter “California Jury Awards Record Damages”].Google Scholar
See id. at 31.Google Scholar
See id. at 32; and The Goodrich Case: Statement of Facts ¶ 5 (visited Feb. 26, 1999) <http://www.aetna.com/news/1999/goodrich-stmnt-of-facts.htm>..>Google Scholar
See Cal. Civ. Code § 3294 (West 1998); and Marquis, supra note 2, at Al.Google Scholar
See Aetna U.S. Healthcare's Statement on the Goodrich Verdict (visited Feb. 26, 1999) <http://www.aetna.com/news/1999/pr_19990121.htm>..' href=https://scholar.google.com/scholar?q=See+Aetna+U.S.+Healthcare's+Statement+on+the+Goodrich+Verdict+(visited+Feb.+26,+1999)+.>Google Scholar
See The Goodrich Case, supra note 5, ¶ 12.Google Scholar
See Aetna U.S. Healthcare's Statement, supra note 7.Google Scholar
See 29 U.S.C. § 1003(b) (1998).Google Scholar
See “California Jury Awards Record Damages,” supra note 3, at 32.Google Scholar
See Access to Quality Care Act of 1999, H.R. 216, 106th Cong. (1999) (visited Mar. 10, 1999) <http://thomas.loc.gov/cgi-bin/query/z?cl06:H.R.216:>; and Marquis, supra note 2, at Al.;+and+Marquis,+supra+note+2,+at+Al.>Google Scholar
See Questions and Answers About the Goodrich Case, Question 7 (visited Feb. 26, 1999) <http://www.aetna.com/news/1999/goodrich_g_and-a.htm>..>Google Scholar
A 1993 California jury verdict of $89 million in a malpractice suit against a health maintenance organization was reduced on appeal. An undisclosed settlement was subsequently reached. See “California Jury Awards Record Damages,” supra note 3, at 33.Google Scholar
See Questions and Answers, supra note 13, at Questions 5, 6.Google Scholar

References

See “Managed Care: HCFA Announces HMO Risk Adjuster, Including Five-Year Phase-In Period,” 8 Health Law Reporter (BNA), Jan. 21, 1999, at 113 [hereinafter “Managed Care”].Google Scholar
See Loewenberg, S., “Health Plans Off to Fast Start,” Legal Times, Feb. 1, 1999, at 4.Google Scholar
See “Managed Care,” supra note 1, at 113.Google Scholar
See Graham, J., “Proposed Medicare Changes Irk HMOs: Payments Would Be Adjusted for Risk,” Chicago Tribune, Jan. 16, 1999, at 4.Google Scholar
See McGinley, L., “Clinton Administration to Phase In Changes in Medicare Payments to HMOs,” Wall Street Journal, Jan. 15, 1999, at B6.Google Scholar
See Loewenberg, supra note 2, at 4.Google Scholar
See Graham, supra note 4, at 4.Google Scholar
See McGinley, supra note 5, at B6.Google Scholar
See Graham, supra note 4, at 4.Google Scholar
See “Medicare Risk Adjustment Phase-In Expected to Save Plans $1.4 Billion in 2000,” Health News Daily, Vol. 11, no. 11, Jan. 19, 1999.Google Scholar
See Loewenberg, supra note 2, at 4.Google Scholar
See Pack, T., “Medicare Cuts Threaten Florida HMOs,” Orlando Sentinel, Jan. 31, 1999, at A1.Google Scholar
See Loewenberg, supra note 2, at 4.Google Scholar
See Graham, supra note 4, at 4.Google Scholar
See Pack, supra note 12, at A1.Google Scholar
See “Managed Care,” supra note 1, at 113.Google Scholar
Id.Google Scholar
See id.Google Scholar
See “Medicare + Choice Adjustments Legislation,” Health News Daily, Vol. 11, no. 22, Feb. 3, 1999; and H.R. 491, 106th Cong. (1999).Google Scholar